Stockreport

Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers

Editas Medicine, Inc.  (EDIT) 
Last editas medicine, inc. earnings: 2/26 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.editasmedicine.com
PDF CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the initiation of IND-enab [Read more]